Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use

AbstractOral desvenlafaxine extended-release [Deller® (Brazil); Pristiq® (USA)] is a second-generation, selective serotonin-noradrenalin reuptake inhibitor that is indicated for the treatment of major depressive disorder (MDD) in adults. In this population, desvenlafaxine is an effective and generally well tolerated treatment, significantly improving symptoms of depression and functional outcomes compared with placebo in 8-week double-blind trials, with these benefits maintained during longer-term therapy. In addition, desvenlafaxine is an effective and generally well tolerated treatment in postmenopausal women with vasomotor symptoms (VMS), significantly reducing the number and severity of hot flushes during 12-week trials, with these benefits maintained during longer-term therapy.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research